Firefly Neuroscience, Inc. filings document the public-company disclosures of an AI precision-neuroscience business focused on EEG/ERP brain analytics and related software platforms. Its Form 8-K reports cover material financing agreements, including securities purchase agreements for unit issuances and at-the-market common stock sales arrangements, along with corporate events affecting its capital structure.
Proxy and annual meeting filings describe Firefly Neuroscience governance matters, including director elections, auditor ratification, incentive plan amendments, common stock voting mechanics and stockholder vote results. The filing record also provides formal disclosure context for the company’s operating model, commercialization activities, equity plan administration and governance obligations as a Nasdaq-listed Delaware corporation.
Firefly Neuroscience (AIFF) reported an insider equity grant. A company director received 73,892 deferred stock units (DSUs) on October 28, 2025 under the 2024 Long‑Term Incentive Plan. The DSUs vest quarterly over 12 months, and each DSU represents the right to receive one share of common stock. Following this transaction, the reporting person held 90,559 derivative securities on a direct ownership basis. The DSUs were reported at a $0.00 price.
Firefly Neuroscience (AIFF) reported a director equity award. On October 28, 2025, the reporting person received 49,262 deferred stock units (DSUs) under the 2024 Long‑Term Incentive Plan. These DSUs vest quarterly over 12 months, and each DSU represents the right to receive one share of common stock.
Following the award, the filing lists 65,929 derivative securities beneficially owned, held directly. The transaction was coded as an acquisition at a stated price of $0.00, consistent with a standard equity grant for board service.
Firefly Neuroscience, Inc. (AIFF) disclosed a Form 4 showing a director received 49,262 deferred stock units (DSUs) on October 28, 2025 under the Issuer's 2024 Long-Term Incentive Plan. The DSUs vest quarterly over 12 months, and each DSU represents the right to receive one share of common stock.
Following the grant, 65,929 derivative securities were beneficially owned, held directly. The transaction price for the DSUs was $0.00.
Firefly Neuroscience (AIFF) amended its definitive proxy to set a single, fixed increase in authorized capital for a stockholder vote. Proposal 4 now asks to raise total authorized shares from 101,000,000 to 5,001,000,000, consisting of 5,000,000,000 Common Stock and 1,000,000 Preferred Stock, via a Certificate of Amendment filed after approval. The revision removes any prior range or Board discretion to pick a number, aligning with Delaware law.
The company states this capacity supports future financing, acquisitions, partnerships, and other corporate purposes. The filing notes potential dilution from future issuances. As of the record date, 13,448,848 shares of Common Stock were outstanding. Proposal 4 is treated as a routine matter; brokers may vote without instructions, and for Proposals 3 and 4, abstentions and broker non-votes have no effect. Approval requires a majority of votes cast. The Board may abandon the amendment before filing even if approved.
Firefly Neuroscience (AIFF): A reporting group led by Windsor Private Capital disclosed open‑market sales of common stock under Rule 144. On 10/20/2025 they sold 33,500 shares at $2.457; on 10/21/2025 they sold 19,222 shares at $2.4004; and on 10/22/2025 they sold 78,031 shares at $2.0727.
Following these transactions, the group states it is no longer a beneficial owner of more than 10% of the company’s securities. After the final sale, 1,236,773 shares were beneficially owned indirectly, held through Windsor, per the filing footnotes.
Firefly Neuroscience (AIFF) insiders reported open‑market sales by a group affiliated with Windsor Private Capital. On 10/15/2025, 17,500 shares were sold at an average price of $2.7444; on 10/16/2025, 40,139 shares at $2.6522; and on 10/17/2025, 45,036 shares at $2.5462. Following these transactions, the group reported 1,452,701, then 1,412,562, and finally 1,367,526 shares beneficially owned. The filing notes these sales were conducted under Rule 144 and that the holdings are reported as indirectly owned through Windsor, with the reporting persons identified as members of a group that beneficially owns more than 10%.
Firefly Neuroscience (AIFF): insider group reports open-market sales
A group of reporting persons led by Windsor Private Capital LP, identified as more than 10% beneficial owners, disclosed multiple sales of Firefly Neuroscience common stock under Rule 144. Reported transactions include sales on 10/09/2025 (30,126 shares at $2.9441), 10/10/2025 (74,810 shares at $2.6994), 10/13/2025 (32,136 shares at $2.6525), and 10/14/2025 (29,500 shares at $2.739). Following these trades, the group reports 1,470,201 shares beneficially owned indirectly.
The securities are held by Windsor; related entities and individuals (including WPC entities and certain officers) may be deemed beneficial owners, with stated disclaimers of beneficial ownership except to the extent of pecuniary interest.
Firefly Neuroscience, Inc. (AIFF) notice shows a proposed sale of 74,810 common shares to be executed through Haywood Securities Inc. on 10/10/2025 on NASDAQ, with an aggregate market value of $201,939.87. The shares were acquired by the selling party on 08/12/2024 as merger consideration, totaling 1,636,990 shares received at that time. The filer reports one sale in the prior three months: 30,126 shares sold on 10/09/2025 for gross proceeds of $86,694.86. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information about the issuer.
Firefly Neuroscience (AIFF) filed a Form 144 notifying the proposed sale of 30,126 shares of common stock, scheduled to be sold on 10/09/2025 on NASDAQ. The filing lists an aggregate market value of $86,694.86 for the shares and shows 13,448,848 shares outstanding, making the block roughly 0.224% of the outstanding stock. The securities were acquired on 08/12/2024 as merger consideration, with 1,636,990 shares received in that transaction. No securities were reported sold by the same person in the past three months. The filer certifies they are not aware of undisclosed material adverse information.
Firefly Neuroscience, Inc. (AIFF) is soliciting proxies for its 2025 Annual Meeting to be held virtually at 10:00 a.m. ET on October 27, 2025. The Board recommends votes FOR five proposals: elect two Class II directors (nominees Brian Posner and Stella Vnook), ratify appointment of Marcum as independent auditor for fiscal 2025, approve an amendment to the equity incentive plan to add 317,820 shares and an annual automatic increase (lower of 4% of outstanding common stock or Board-determined amount) from January 1, 2026 through January 1, 2035, authorize the Board to increase authorized shares up to an aggregate of 5,001,000,000 (including 1,000,000 preferred shares), and allow adjournment if needed to solicit additional proxies. Materials including the 2024 Form 10-K are available at www.proxyvote.com and the virtual meeting website. The proxy describes Board composition, committee charters, indemnification and director compensation (option awards for non-employee directors), and discloses pay-versus-performance information noting that net loss increased from 2023 to 2024 while compensation actually paid (CAP) to NEOs increased. Voting methods (Internet, mail, virtual) and quorum/broker-vote rules are explained.